anti-BAFF (mouse), mAb (blocking) (Sandy-2) (preservative free)
Method: Wild type C57BL/6 mice were treated i.p. at day 0 (single administration) with monoclonal antibody anti-BAFF (mouse), mAb (Sandy-2) (preservative free) (at 2mg/kg). Lymph nodes were prepared at week 2 and analyzed by FACS for the presence of T (CD3) and B (CD19) cells. Untreated BAFF WT and KO mice were analyzed in parallel.
|Synonyms||BLyS; TALL-1; CD257; B Cell Activating Factor; TNFSF13B|
|Product Type||Monoclonal Antibody|
|Source/Host||Purified from concentrated hybridoma tissue culture supernatant.|
|Immunogen/Antigen||Recombinant mouse BAFF.|
Functional Application: Inhibition of mouse BAFF binding to BAFF-R and TACI (BCMA not tested); blocks BAFF activity in mice. Injection of the anti-BAFF (mouse), mAb (Sandy-2) in mice creates a BAFF KO phenotype within 2 weeks, that can be maintained as long as necessary (> 6 months) by further injections of Sandy-2 every 2 weeks.
Recognizes mouse BAFF.
|Purity Detail||Protein G-affinity purified.|
|Endotoxin Content||<0.01EU/μg purified protein (LAL test; Lonza).|
|Formulation||Liquid. In PBS.|
|Isotype Negative Control|
|Shipping and Handling|
|Short Term Storage||+4°C|
|Long Term Storage||+4°C|
|Handling Advice||Do not freeze.|
|Use/Stability||Stable for at least 1 year after receipt when stored at +4°C.|
|Product Specification Sheet|
BAFF is a master regulator of peripheral B cell survival and, together with IL-6, promotes Ig class-switching and plasma cell differentiation. BAFF co-stimulates activated T cells. Increased levels of soluble BAFF have been detected in the serum of patients with various autoimmune diseases, such as Sjögren’s syndrome, rheumatoid arthritis, multiple sclerosis and systemic lupus erythematosus (SLE). Furthermore, BAFF is found in inflammatory sites in which there is lymphoid neogenesis. BAFF levels are elevated in patients with multiple myeloma and B cell chronic lymphoid leukemia (B-CCL).
- The B cell-stimulatory cytokines BLyS and APRIL are elevated in human periodontitis and are required for B cell-dependent bone loss in experimental murine periodontitis: T. Abe, et al.; J. Immunol. 195, 1427 (2015)
- Antibodies that block or activate mouse B cell activating factor of the TNF family (BAFF) respectively induce B cell depletion or B cell hyperplasia: C. Kowalczyk-Quintas, et al.; J. Biol. Chem. 291, 19826 (2016)
- Interactions between fibroblastic reticular cells and B cells promote mesenteric lymph node lymphangiogenesis: L.K. Dubey, et al.; Nat. Commun. 8, 367 (2017)
- The unknown aspect of BAFF: Inducing IL-35 production by a CD5+CD1dhiFcγRIIbhi regulatory B-Cell subset in lupus: Y. Zhang, et al.; J. Invest. Dermatol. 137, 2532 (2017)
- Berberine demonstrates anti-inflammatory properties in Helicobacter pylori-infected mice with chronic gastritis by attenuating the Th17 response triggered by the B cell-activating factor: X. Wu, et al.; J. Cell. Biochem. 119, 5373 (2018)
- A loop region of BAFF controls B cell survival and regulates recognition by different inhibitors: M. Vigolo, et al.; Nat. Commun. 9, 1199 (2018)
- Healthy donor polyclonal IgMs diminish B-lymphocyte autoreactivity, enhance regulatory T cell generation, and reverse type 1 diabetes in NOD mice: C.S. Wilson, et al.; Diabetes 67, 2349 (2018)
- B2-Lymphocyte responses to oxidative stress-derived antigens contribute to the evolution of nonalcoholic fatty liver disease (NAFLD): S. Bruzzi, et al.; Free. Radic. Biol. Med. 124, 249 (2018)
- Depletion of BAFF cytokine exacerbates infection in Pseudomonas aeruginosa infected mice: D. Garic, et al.; J. Cyst. Fibr. 18, 349 (2019)